Fluidda NV

Fluidda NV is a global leader in Functional Respiratory Imaging (FRI), a proprietary technology that combines high-resolution CT (HRCT) scans with Computational Fluid Dynamics (CFD) and artificial intelligence to advance respiratory healthcare. The company operates as both a Contract Research Organization (CRO) and a clinical decision-support partner, serving pharmaceutical, biotech, and healthcare organizations in drug development, medical device validation, and patient diagnosis and monitoring. Fluidda's FRI technology enables detailed regional lung functionality assessment, personalized treatment optimization, and accelerated clinical trial design for respiratory conditions including asthma, COPD, cystic fibrosis, and other pulmonary diseases. The platform provides clinicians and researchers with visualization and quantitative analysis of airflow patterns and regional lung physiology beyond standard spirometry, supporting precision medicine approaches. Fluidda recently joined Banook, a global clinical trial services organization, enhancing its capacity to deliver end-to-end respiratory drug and device development solutions. The company serves healthcare systems, pulmonologists, radiologists, and respiratory researchers worldwide, with demonstrated applications in real-world clinical practice and public health initiatives. Fluidda's technology reduces clinical trial timelines, improves cost-effectiveness, and supports evidence-based treatment selection for better patient outcomes in respiratory disease management.